At the time of writing, AnaptysBio Inc [ANAB] stock is trading at $24.10, up 8.22%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The ANAB shares have gain 27.65% over the last week, with a monthly amount drifted -24.76%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
AnaptysBio Inc [NASDAQ: ANAB] stock has seen the most recent analyst activity on July 22, 2024, when H.C. Wainwright initiated its Buy rating and assigned the stock a price target of $55. Previously, JP Morgan upgraded its rating to Overweight on July 19, 2024, and elevated its price target to $69. On April 16, 2024, Leerink Partners initiated with a Outperform rating and assigned a price target of $47 on the stock. Wells Fargo started tracking the stock assigning a Overweight rating and suggested a price target of $56 on April 11, 2024. Wedbush upgraded its rating to a Outperform and raised its price target to $34 on March 12, 2024. BTIG Research started tracking with a Buy rating for this stock on February 26, 2024, and assigned it a price target of $55. In a note dated February 21, 2024, Stifel initiated an Buy rating and provided a target price of $50 on this stock.
For the past year, the stock price of AnaptysBio Inc fluctuated between $13.36 and $41.31. Currently, Wall Street analysts expect the stock to reach $52 within the next 12 months. AnaptysBio Inc [NASDAQ: ANAB] shares were valued at $24.10 at the most recent close of the market. An investor can expect a potential return of 115.77% based on the average ANAB price forecast.
Analyzing the ANAB fundamentals
According to AnaptysBio Inc [NASDAQ:ANAB], the company’s sales were 57.17M for trailing twelve months, which represents an 804.67% jump. Gross Profit Margin for this corporation currently stands at 0.96% with Operating Profit Margin at -2.58%, Pretax Profit Margin comes in at -2.9%, and Net Profit Margin reading is -2.9%. To continue investigating profitability, this company’s Return on Assets is posted at -0.34, Equity is -2.88 and Total Capital is -0.33. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.02.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 22.58 points at the first support level, and at 21.06 for the second support level. However, for the 1st resistance point, the stock is sitting at 25.36, and for the 2nd resistance point, it is at 26.63.
Ratios To Look Out For
It is important to note that AnaptysBio Inc [NASDAQ:ANAB] has a current ratio of 10.23. In addition, the Quick Ratio stands at 10.23 and the Cash Ratio stands at 4.37. Considering the valuation of this stock, the price to sales ratio is 13.49, the price to book ratio is 8.69.
Transactions by insiders
Recent insider trading involved Lizzul Paul F., Chief Medical Officer, that happened on Sep 23 ’24 when 1500.0 shares were sold. Officer, PAUL F LIZZUL completed a deal on Sep 23 ’24 to buy 1500.0 shares. Meanwhile, CHIEF LEGAL OFFICER LOUMEAU ERIC J sold 8720.0 shares on Sep 16 ’24.
